- Science Behind CYTOSYDE -

NATURAL LUNG THERAPY

shutterstock_1727242633.jpg
CYTOSYDE™ "SFJD"
 
SHUFENG JIEDU, a promising herbal therapy for moderate COVID: Antiviral and anti-inflammatory properties, pathways of bioactive compounds, and a clinical real-world pragmatic study*.
*Phytomedicine

Available online 22 October 2020, 153390

60K People Treated in Germany

 and over 100M People in China  

Screen Shot 2021-01-27 at 4.13.09 PM.png
WHO LOGO.jpeg

PUBLISHED MEDICAL DATA:

 

16 scientific studies on the WHO site:

Over 90 Independent Scientific Studies Published:

Important Study on Phyto Medicine:

PHARMACEUTICAL FORM:  Capsules in a containerDry herbal ingredients contained inside hard gel capsules

RECOMMENDED CONSUMPTION/ MODE OF APPLICATION: For a daily dose, take 4 capsules, 3 x daily for 3 days.

 

DAILY DOSAGE:   12 capsules

MODE OF ACTION:  Enhances immune function; .  Maximizesing the body's natural immune potential.

DURATION OF APPLICATION:  3 days

SUITABLE FOR: Adults

 

SPECIAL USE GROUPS: Nil

KNOWN SIDE-EFFECTS: occasionally light stool.

REGULATORY CONTROLE - EU

German release protocol according to Europ. pharmaceutical law by an technical authorities based on quality checks carried out in Germany with regard to the composition and quantity of the constituents in accordance with the criteria of the new international ISO standard 19609 (currently being published), as well as all relevant tests with regard to undesirable contamination, such as by heavy metals (mercury, lead and cadmium), pesticides (approximately 300 different approved pesticides), microbial exposures (bacteria, yeasts and mould, E.coli and salmonella), and aflatoxine (B1, G1, B2, G2) according to European pharmaceutical criteria. The raw materials used were also tested in accordance with the quality criteria of the Chinese Pharmacopoeia for all 8 raw materials and officially approved as active substances in accordance with the quality criteria of the Chinese Pharmacopoeia in force in China.


The production data is fully available to regulatory inspectors on the state medical server in China for each single batch, as this product is considered a medicine in China and must, therefore, meet all safety criteria. This also applies to the export goods that have been sent to Germany for inspection.

INTERNATIONAL SITUATION:

Within the scope of the European Pharmacopoeia, the proven efficacy means that pharmaceutical authorization as a pharmaceutical is required. However, it is at the discretion of the respective national authorities to allow this natural product as a dietary supplement. This does not require time-consuming approval and the product could be brought directly onto the market after communication with the competent authorities. This is possible because this natural 8-plant mixture has been intensively researched for decades in terms of its risks and side effects. In addition no health risks could be identified.  Within the scope of the American Pharmacopoeia and that of related countries (e.g. South America, Canada, etc.), the product cannot, from a legal point of view, constitute a medicinal product (plant origin) and should, therefore, generally be regarded as a dietary supplement. The decision has also been given by the respective national authorities in the context of a case-by-case decision.  In all other countries, classification as a medicine or dietary supplement is regulated independently nationally.